Type 1 Diabetes Addressed By “Silencing Immune Attacks” (Children’s Hospital, Boston)

2 Min Read

Image

Researchers at Children’s Hospital in Boston have reported in the online edition of Diabetes that they have identified the specific molecular pathway involved in triggering the autoimmune response at the root of type 1 diabetes. The research team studied “hundreds” of pathways in animals with diabetes and ultimately identified one, known as ATP/P2X7R, which triggers the immune system’s T-cell attacks on the pancreas that subsequently prevent the pancreas from producing insulin.

While this research is akin in some ways to many disease research discoveries that are dramatic but that have not led to cures or significant advances in treatment, the discovery of the root pathway in type 1 diabetes is significant for the fact that it opens up the possibility of, on the one hand, interrupting this pathway in order to the autoimmune destruction of patients’ insulin-producing islet cells and, on the other hand, interrupting this pathway to similarly prevent destruction of islet transplant cells. It may well be years before this leads to treatment options, which may include “drug therapies to transplants that require less immunosuppression” for patients with existing type 1 diabetes and options to even prevent type 1 from developing in children.

     

TAGGED:
Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version